Patent ID: 9724325
Date: 2017-08-08
CPC Classifications: A61K,A61P,B82Y

Claim:
1. A treatment regimen for a patient undergoing cancer radiation therapy comprising: administration of a therapeutically effective amount of a genistein formulation to the patient during an administration period that commences up to six days prior to commencement of the cancer radiation therapy, the genistein formulation comprising: (i) nanoparticulate genistein; and (ii) a pharmaceutically acceptable suspension medium comprising an aqueous carrier, wherein the nanoparticulate genistein exhibits a particle size distribution characterized by a D (0.50) of 0.5 μm or less, and wherein the nanoparticulate genistein is present in the formulation at a concentration of between 250 mg/ml and 500 mg/ml.